(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

Bullish option flow detected in Amgen (AMGN) with 8,403 calls trading, 2x expected, and implied vol increasing over 3 points to 49.64%. Jan-25 ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

Every step of the way, Rose Booker, formally of the Durham Catholic District School Board, has worked tirelessly to make sure ...

Potential Phase 1b initiation in one or more tumor types is anticipated in 2025 pending the selection of an optimized dose ...

US endocrinologists are favoring antithyroid drugs over radioactive iodine in initial Graves’ disease treatment, and new ...

For the most current information about the device indications for the therapeutic products in this group, go to: ...

Vitrian, the leading end-to-end provider of investment capital and capacity building services for biomanufacturing, announced today that it closed a $50 million investment, with ability to scale to ...

Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...

If you don’t know what Net Investment Income Tax (NIIT) is, you’re not alone. This relatively new tax began a little over a decade ago but the number of taxpayers subject to the tax has increased.

THOUSAND OAKS, Calif., Oct. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024.